Fluoxetine Ameliorates Atopic Dermatitis-Like Skin Lesions in BALB/c Mice through Reducing Psychological Stress and Inflammatory Response.
Atopic dermatitis (AD) is a common chronic inflammatory skin disorder, and patients with AD suffer from severe psychological stress, which markedly increases the prevalence rate of depression and anxiety disorders in later life. Fluoxetine, a selective serotonin reuptake inhibitor, has recently been reported to exert anti-inflammatory and immunosuppressive effects. However, it is unclear whether fluoxetine is effective in the treatment of AD through reducing psychological stress and inflammatory reaction. Here, we reported that a BALB/c mouse model of AD was induced by application of 2,4-dinitrochlorobenzene (DNCB) onto hairless dorsal skin. Chronic fluoxetine treatment (10 mg/kg per day, i.p.) significantly attenuated AD-like symptoms, as reflected by a dramatic decrease in scratching bouts, as well as a decrease in anxiety- and depressive-like behaviors. Furthermore, these behavioral changes were accompanied by a significant decrease in epidermal thickness, the number of mast cells in skin tissue, mRNA levels of interleukin-4 (IL-4) and IL-13 in the spleen, as well as serum immunoglobulin E (IgE) in the DNCB-treated mice by treatment with fluoxetine. Taken together, these results indicate that fluoxetine may suppress psychological stress and inflammatory response during AD development, and subsequently ameliorate AD symptoms, suggesting that fluoxetine may be a potential therapeutic agent against AD in clinic.
Chongqing Key Laboratory of Translational Medical Research in Cognitive Development and Learning and Memory Disorders, Children's Hospital of Chongqing Medical UniversityChongqing, China; Ministry of Education Key Laboratory of Child Development and Disorders, Children's Hospital of Chongqing Medical UniversityChongqing, China; The Chongqing Hospital of Traditional Chinese MedicineChongqing, China.
Yanxi
Y
Li
Chongqing Key Laboratory of Translational Medical Research in Cognitive Development and Learning and Memory Disorders, Children's Hospital of Chongqing Medical UniversityChongqing, China; Ministry of Education Key Laboratory of Child Development and Disorders, Children's Hospital of Chongqing Medical UniversityChongqing, China.
Long
L
Chen
Chongqing Key Laboratory of Translational Medical Research in Cognitive Development and Learning and Memory Disorders, Children's Hospital of Chongqing Medical UniversityChongqing, China; Ministry of Education Key Laboratory of Child Development and Disorders, Children's Hospital of Chongqing Medical UniversityChongqing, China.
Yehong
Y
Du
Chongqing Key Laboratory of Translational Medical Research in Cognitive Development and Learning and Memory Disorders, Children's Hospital of Chongqing Medical UniversityChongqing, China; Ministry of Education Key Laboratory of Child Development and Disorders, Children's Hospital of Chongqing Medical UniversityChongqing, China.
Daochao
D
Huang
Chongqing Key Laboratory of Translational Medical Research in Cognitive Development and Learning and Memory Disorders, Children's Hospital of Chongqing Medical UniversityChongqing, China; Ministry of Education Key Laboratory of Child Development and Disorders, Children's Hospital of Chongqing Medical UniversityChongqing, China.
Huili
H
Han
Chongqing Key Laboratory of Translational Medical Research in Cognitive Development and Learning and Memory Disorders, Children's Hospital of Chongqing Medical UniversityChongqing, China; Ministry of Education Key Laboratory of Child Development and Disorders, Children's Hospital of Chongqing Medical UniversityChongqing, China.
Zhifang
Z
Dong
anti-inflammation; atopic dermatitis; fluoxetine; itching; psychological stress
J Pain Symptom Manage. 2003 Dec;26(6):1105-12
14654262
Clin Exp Allergy. 2001 Sep;31(9):1344-51
11591183
Acta Derm Venereol. 2009;89(1):45-51
19197541
J Invest Dermatol. 1976 Sep;67(3):305-12
965785
Science. 1987 May 22;236(4804):944-7
3107127
Lancet. 2016 Mar 12;387(10023):1109-22
26377142
Int J Clin Exp Pathol. 2011 Jan 05;4(2):162-8
21326811
PLoS One. 2014 Aug 29;9(8):e104938
25170825
J Invest Dermatol. 1995 Dec;105(6):749-55
7490467
Int Immunopharmacol. 2014 May;20(1):148-56
24613205
J Allergy Clin Immunol. 1990 May;85(5):927-33
2185294
Bipolar Disord. 2003;5 Suppl 2:20-35
14700010
Int J Dermatol. 1993 Sep;32(9):656-60
8407093
Expert Opin Investig Drugs. 2015 Jan;24(1):61-68
25201033
Mediators Inflamm. 2014;2014:319438
25132731
Hum Psychopharmacol. 2010 Apr;25(3):201-15
20373471
J Allergy Clin Immunol. 2006 Jul;118(1):24-34; quiz 35-6
16815134
J Dermatol Sci. 2007 Sep;47(3):244-7
17604608
J Am Acad Dermatol. 2005 Jul;53(1 Suppl 1):S50-8
15968264
Clin Rev Allergy Immunol. 2011 Dec;41(3):298-310
21249468
J Dermatol Sci. 1997 Jan;14(1):63-7
9049809
Cell Calcium. 2015 Sep;58(3):254-63
26115837
Brain Behav Immun. 2002 Apr;16(2):87-103
11908920
Sci Rep. 2015 Jul 28;5:12667
26218751
Am Fam Physician. 2012 Jul 1;86(1):35-42
22962911
BMC Complement Altern Med. 2015 Oct 14;15:353
26467986
Allergol Immunopathol (Madr). 1990 Nov-Dec;18(6):321-4
2088101
J Affect Disord. 2015 Jun 1;178:60-5
25795537
J Neuroimmune Pharmacol. 2013 Sep;8(4):934-43
23640520
Curr Opin Pharmacol. 2009 Feb;9(1):24-30
19157982
J Ethnopharmacol. 2008 Mar 5;116(2):270-8
18191513
Mol Brain. 2011 Mar 08;4:10
21385396
Int Immunol. 1997 Mar;9(3):461-6
9088984
J Clin Med. 2015 Apr 03;4(4):593-613
26239349
J Dermatol Sci. 2005 Mar;37(3):159-67
15734285
Curr Opin Allergy Clin Immunol. 2008 Oct;8(5):423-7
18769195
Allergy. 1992 Apr;47(2 Pt 1):65-75
1632481
J Clin Invest. 2004 Mar;113(5):651-7
14991059